Biodesix Stock Performance

BDSX Stock  USD 1.40  0.01  0.71%   
The firm shows a Beta (market volatility) of -0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Biodesix are expected to decrease at a much lower rate. During the bear market, Biodesix is likely to outperform the market. At this point, Biodesix has a negative expected return of -0.25%. Please make sure to confirm Biodesix's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Biodesix performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biodesix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1
Disposition of 434 shares by Gary Pestano of Biodesix at 1.4795 subject to Rule 16b-3
09/04/2024
2
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
10/07/2024
3
Disposition of 327 shares by Robin Cowie of Biodesix subject to Rule 16b-3
10/11/2024
4
Acquisition by Scott Hutton of 180926 shares of Biodesix at 1.46 subject to Rule 16b-3
10/22/2024
5
Acquisition by Vazquez Chris of tradable shares of Biodesix subject to Rule 16b-3
10/25/2024
6
What To Expect From Biodesix Inc Q3 2024 Earnings
10/31/2024
7
Biodesix Announces Third Quarter 2024 Results and Highlights
11/01/2024
8
Biodesix, Inc. Q3 2024 Earnings Call Transcript
11/04/2024
9
Acquisition by Kennedy Lawrence T. Jr of 51200 shares of Biodesix at 1.365 subject to Rule 16b-3
11/05/2024
10
Biodesix director Matthew Strobeck acquires 55,915 in stock
11/06/2024
11
Biodesix, Inc. Shares Bought by Perkins Capital Management Inc.
11/07/2024
12
Disposition of 500 shares by Robin Cowie of Biodesix at 1.3909 subject to Rule 16b-3
11/11/2024
13
Disposition of 471 shares by Robin Cowie of Biodesix at 1.4008 subject to Rule 16b-3
11/12/2024
14
Biodesix chief commercial officer sells shares worth 644
11/13/2024
Begin Period Cash Flow43.2 M
  

Biodesix Relative Risk vs. Return Landscape

If you would invest  174.00  in Biodesix on August 16, 2024 and sell it today you would lose (34.00) from holding Biodesix or give up 19.54% of portfolio value over 90 days. Biodesix is currently does not generate positive expected returns and assumes 4.1943% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Biodesix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Biodesix is expected to under-perform the market. In addition to that, the company is 5.51 times more volatile than its market benchmark. It trades about -0.06 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of volatility.

Biodesix Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Biodesix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biodesix, and traders can use it to determine the average amount a Biodesix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0594

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsBDSX

Estimated Market Risk

 4.19
  actual daily
37
63% of assets are more volatile

Expected Return

 -0.25
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.06
  actual daily
0
Most of other assets perform better
Based on monthly moving average Biodesix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biodesix by adding Biodesix to a well-diversified portfolio.

Biodesix Fundamentals Growth

Biodesix Stock prices reflect investors' perceptions of the future prospects and financial health of Biodesix, and Biodesix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biodesix Stock performance.

About Biodesix Performance

Evaluating Biodesix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Biodesix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biodesix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado. Biodesix operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 218 people.

Things to note about Biodesix performance evaluation

Checking the ongoing alerts about Biodesix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biodesix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biodesix generated a negative expected return over the last 90 days
Biodesix may become a speculative penny stock
Biodesix has high historical volatility and very poor performance
Biodesix has a very high chance of going through financial distress in the upcoming years
Biodesix currently holds 60.69 M in liabilities with Debt to Equity (D/E) ratio of 3.2, implying the company greatly relies on financing operations through barrowing. Biodesix has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biodesix's use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 49.09 M. Net Loss for the year was (52.15 M) with profit before overhead, payroll, taxes, and interest of 24.06 M.
Biodesix currently holds about 15.18 M in cash with (22.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Roughly 47.0% of Biodesix shares are held by company insiders
Latest headline from investing.com: Biodesix chief commercial officer sells shares worth 644
Evaluating Biodesix's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biodesix's stock performance include:
  • Analyzing Biodesix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biodesix's stock is overvalued or undervalued compared to its peers.
  • Examining Biodesix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Biodesix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biodesix's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Biodesix's stock. These opinions can provide insight into Biodesix's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biodesix's stock performance is not an exact science, and many factors can impact Biodesix's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Biodesix Stock Analysis

When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.